Marea Therapeutics doses first patient in MAR002 phase 2 trial

Marea Therapeutics, a subsidiary of Lisata Therapeutics, Inc., has successfully administered the first dose of its investigational drug MAR002 in a Phase 2 clinical trial aimed at treating acromegaly. MAR002 is an allosteric monoclonal antibody targeting the growth hormone receptor, designed to address acromegaly, a rare endocrine disorder characterized by excess growth hormone production.

The trial will enroll around 72 participants across three dose arms, with the primary goal of measuring IGF-1 reduction after 10 weeks of treatment. Preliminary results from a Phase 1 study conducted in June indicated promising IGF-1 suppression and a dosing frequency potentially as infrequent as once every two weeks, compared to the current standard of daily subcutaneous injections.

Acromegaly affects approximately 30,000 patients in the U.S., often leading to severe health complications and a reduced lifespan.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.